Chilmark’s 2021 predictions were mostly accurate, but could have been more daring. Our outlook on 2022 is forthcoming and will include some tougher calls.
Looking Back: Reviewing Our 2021 Predictions
read more
Chilmark’s 2021 predictions were mostly accurate, but could have been more daring. Our outlook on 2022 is forthcoming and will include some tougher calls.
Roughly two years after we reviewed the first FDA guidance on Clinical Decision Support (CDS), FDA...